A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.

@article{Shearer2009ADP,
  title={A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.},
  author={James Shearer and Shane Darke and Craig Rodgers and Tim Slade and Ingrid Van Beek and John Lewis and D Brady and Rebecca McKetin and Richard P. Mattick and Alex Wodak},
  journal={Addiction},
  year={2009},
  volume={104 2},
  pages={224-33}
}
AIM To examine the safety and efficacy of modafinil (200 mg/day) compared to placebo in the treatment of methamphetamine dependence and to examine predictors of post-treatment outcome. PARTICIPANTS AND DESIGN Eighty methamphetamine-dependent subjects in Sydney, Australia were allocated randomly to modafinil (200 mg/day) (n = 38) or placebo (n = 42) under double-blind conditions for 10 weeks with a further 12 weeks post-treatment follow-up. MEASURES Comprehensive drug use data (urine… CONTINUE READING